Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Key Inclusion Criteria:

1. Diagnosis of IPF as defined by American Thoracic Society/European RespiratorySociety/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) guidelines within the past 7 years prior to study participation.

2. High-resolution computed tomography (HRCT) scan at Screening, with ≥10% to <50%parenchymal fibrosis (reticulation) and <25% honeycombing.

3. FVCpp value >45% and <95% at Screening and Day 1 (prior to randomization).

4. Diffusing capacity of the lungs for carbon monoxide (DLCO) percent predicted ≥25%and ≤90%.

5. Not currently receiving treatment for IPF with an approved therapy for IPF (such as,pirfenidone or nintedanib) for any reason, including prior intolerance or lack ofresponse to an approved IPF therapy, or choice to forego treatment with an approvedIPF therapy after a full discussion with the Investigator regarding risks/benefitsof such therapy.

Key Exclusion Criteria:

1. Previous exposure to pamrevlumab.

2. Evidence of significant obstructive lung disease, as evidenced by spirometry orHRCT.

3. Female participants who are pregnant or nursing.

4. Smoking within 3 months of Screening and/or unwilling to avoid smoking throughoutthe study.

5. Interstitial lung disease other than IPF.

6. Sustained improvement in the severity of IPF during the 12 months prior toscreening.

7. Other types of respiratory diseases that, in the opinion of the Investigator, wouldimpact the primary protocol endpoint or otherwise preclude participation in thestudy, including diseases of the airways, lung parenchyma, pleural space,mediastinum, diaphragm, or chest wall.

8. Certain medical conditions, that, in the opinion of the Investigator, would impactthe primary protocol endpoint or otherwise preclude participation in the study (suchas, myocardial infarction/stroke, severe chronic heart failure, pulmonaryhypertension, or cancers).

9. Acute IPF exacerbation during Screening or Randomization including hospitalizationdue to acute IPF exacerbation within 4 weeks prior to or during screening.

10. Use of any investigational drugs or unapproved therapies, or participation in anyclinical trial with an investigational new drug within 30 days prior to screening.Or use of approved IPF therapies (such as, pirfenidone or nintedanib) within 1 weekprior to screening.

11. History of allergic or anaphylactic reaction to human, humanized, chimeric or murinemonoclonal antibodies, or to any component of the excipient.